Evaluation of Recombinant Human Bone Morphogenetic Protein‐2 on the Repair of Alveolar Ridge Defects in Baboons

Miranda, Dario Augusto Oliveira; Blumenthal, Neil M.; Sorensen, Rachel G.; Wozney, John M.; Wikesjö, Ulf M.E.

doi:10.1902/jop.2005.76.2.210

Cited by 49 publications

(46 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BMPs have been shown to increase the formation of bone nodules in vitro [45][46][47][48][49][50][51][52][53][54][55][56] and stimulate bone formation in vivo. But the dosage applied in these clinical studies was several orders of magnitude higher than the concentration of naturally occurring BMPs [57].…”

Section: Discussionmentioning

confidence: 99%

The effect of growth factors for bone augmentation to enable dental implant placement: A systematic review

Shimono

Oshima

Arakawa

et al. 2010

Japanese Dental Science Review

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The effect of growth factors for bone augmentation to enable dental implant placement: A systematic review

Shimono

Oshima

Arakawa

et al. 2010

Japanese Dental Science Review

View full text Add to dashboard Cite

“…[17][18][19][20] BCP has been also used as a carrier for rhBMP-2 in the alveolar ridge defect 21 and spine fusion 22,23 models. Jung et al 24 evaluated rhBMP-2-loaded HA/TCP in the rabbit calvarial onlay model, and concluded that this might be an ideal carrier system for rhBMP-2.…”

Section: Introductionmentioning

confidence: 99%

Recombinant Human Bone Morphogenetic Protein-2 Stimulates the Osteogenic Potential of the Schneiderian Membrane: A Histometric Analysis in Rabbits

Youngik

Lee

Kim

et al. 2013

Tissue Engineering Part A

View full text Add to dashboard Cite

This study evaluated the osteoinductive effect of the recombinant human bone morphogenetic protein-2 (rhBMP-2)-coated biphasic calcium phosphate (BCP) carrier system on the grafted sinus area, including surrounding tissues and the Schneiderian membrane. A total of 18 male rabbits were used in this study; two for in vitro and 16 for in vivo experiments. Schneiderian membranes taken from two animals were cultured with or without rhBMP-2, and quantitative reverse transcriptase-polymerase chain reaction analysis was performed. Both maxillary sinuses in each of the 16 animals were used to compare the in vivo effects of rhBMP-2-coated BCP (experimental group) and BCP alone (control group). In each animal, rhBMP-2-coated BCP was grafted into one of the maxillary sinuses, and the same amount of BCP alone was grafted into the contralateral site in random order. Radiologic and histometric analyses were performed at 2 and 8 weeks after surgery. After 2 days of culturing with or without rhBMP-2, a significant increase in the expression of early osteoblasts (RUNX2, type I collagen, alkaline phosphatase, and osteopontin) could be observed. Different histologic healing patterns were observed in experimental and control sites: newly formed bone lining the reflected sinus membrane without bone formation was observed at the central areas of experimental sites (window=0.06%; center=0%; membrane=20.86% of new bone), whereas evenly distributed new bone formation was observed at the control sites (window=7.27%; center=7.41%; membrane=15.58% of new bone).The augmented volume was well maintained at both the experimental and control sites during the experimental period, but at 2 weeks, the augmented volume was greater at the experimental sites than at the control sites (232.62 and 195.29 mm(3), respectively; p<0.001). These results suggest that good space maintenance in sinus augmentation is achieved with BCP, while the osteoinductive potential of the sinus membrane is activated at the early stage of healing with rhBMP-2.

show abstract

“…They have included dose-variation (Tatakis et al 2002), the use of space-providing macroporous membranes or titanium mesh devices to shield the rhBMP-2/ACS from compressive forces reducing the potential volume for tissue to form into Lee et al 2013b), as well as supplementing the ACS with bulking agents to withstand compressive forces compromising bone augmentation (Barboza et al 2000(Barboza et al , 2004Miranda et al 2005;Lu et al 2013). Whereas Sigurdsson et al (1997), figure copyrighted by and modified with permission from Wiley-Blackwell dose-variation (rhBMP-2 at 0.05, 0.1, and 0.2 mg/mL) significantly failed to influence rhBMP-2/ACS-induced bone formation (Tatakis et al 2002), the use of macroporous space-providing devices allowed significantly enhanced rhBMP-2/ACS (rhBMP-2 at 0.2 mg/mL)-induced bone formation/alveolar augmentation compared with unshielded sites supporting the tissue engineering principle that the geometry/volume of new bone formation can be ascertained in the design of a space-providing device/matrix (Fig.…”

Section: Alveolar Augmentationmentioning

confidence: 99%

“…However, bulking agents also introduce compromises related to biodegradation; slowly or nonresorbable biomaterials may compromise the structural integrity of the newly formed bone including osseointegration of dental implants (Barboza et al 2000(Barboza et al , 2004Miranda et al 2005;Lu et al 2013) while for bioresorbable conduits the resorption process per se may solicit inflammatory reactions compromising bone formation and/or maintenance (Sigurdsson et al 1996). Critical-size, supraalveolar, peri-implant defects treated with rhBMP-2/ACS (0.2 mg/ mL), a porous, space-providing ePTFE membrane for guided tissue regeneration, or rhBMP-2/ACS combined with the porous, ePTFE membrane.…”

Section: Alveolar Augmentationmentioning

confidence: 99%

Alveolar Augmentation: Focus on Growth Factors (BMPs)

Wikesjö

Susin

Lee

2014

Mechanical Engineering Series

View full text Add to dashboard Cite

Surgical placement of dental implants is governed by the prosthetic design and the morphology and quality of the alveolar bone. Often, implant placement may be difficult, if at all possible, due to alveolar ridge aberrations. In consequence, prosthetically dictated implant positioning commonly entails bone augmentation procedures. We herein discuss the unique biologic potential, the clinical relevance, and perspectives of bone morphogenetic protein (BMP) technologies (focus on rhBMP-2) for alveolar bone augmentation. We also address merits and short-comings of current treatment protocol including bone biomaterials and guided bone regeneration (GBR). In perspective, our studies suggest that BMPs have an unparalleled, dose-dependent potential to augment alveolar bone and in turn support dental implant fixation and functional loading. Inclusion of BMPs for alveolar augmentation to facilitate dental implant fixation may thus not only enhance predictability of existing clinical protocol but radically change current treatment paradigms making conventional "grafting" and GBR procedures altogether obsolete.

show abstract

Evaluation of Recombinant Human Bone Morphogenetic Protein‐2 on the Repair of Alveolar Ridge Defects in Baboons

Cited by 49 publications

References 25 publications

The effect of growth factors for bone augmentation to enable dental implant placement: A systematic review

The effect of growth factors for bone augmentation to enable dental implant placement: A systematic review

Recombinant Human Bone Morphogenetic Protein-2 Stimulates the Osteogenic Potential of the Schneiderian Membrane: A Histometric Analysis in Rabbits

Alveolar Augmentation: Focus on Growth Factors (BMPs)

Contact Info

Product

Resources

About